Over the past three decades, transplantation has become the preferred approach to the treatment of failure of the heart, liver, kidneys, and lungs. Recently, a progressive improvement in allograft survival, in particular kidney allografts, has been reported. Intriguingly, this improvement was seen only in recipients who had never experienced an acute rejection episode, emphasizing the recipient's alloimmune response as a major determinant of overall outcome of the transplant. However, this therapy is not entirely satisfactory because the recipient must be treated with immunosuppressive agents that trade the morbidity and mortality of organ failure for the risks of infection and cancer. These drugs also likely contribute to increased mortality from cardiovascular disease, the major cause of premature death in kidney transplant recipients. In addition, there is the problem of chronic rejection, which arises at least in part because immunosuppressive strategies do not completely inhibit alloimmune responses, and results in slow progressive deterioration in graft function. These challenges, together with the increasing demand for organs for transplantation, create an urgent need for optimizing the outcome of transplantation by achieving long-term, drug-free, graft acceptance with normal organ function. Ever since the seminal experiments conducted by Billingham, Brent, and Medawar in 1953, there was unequivocal proof of the concept that specific tolerance to a defined set of donor antigens can be acquired throughout life. The fact that functional tolerance is not genetically encoded on specific genes has been the fundamental scientific basis for a broad spectrum of investigations to design possible strategies to alter human immunologic response patterns. Achieving the specific goal of donor-specific tolerance not only would minimize the recipient's risk for serious side effects, resulting in continuous immunosuppressive therapy, but also would prevent loss of long-term graft function caused by chronic rejection processes.
Recently, numerous insights into the dynamic interrelationship of host immune responses elicited by donor antigen presentation, either on the graft itself or on specialized antigen-presenting cells, have substantially broadened our understanding of the cascade of events that results in the acquisition of tolerance. By definition, tolerance can be described in general terms as a state of unresponsiveness to self or foreign antigens in the absence of immunosuppressive therapy. It is inferred that the tolerogenic state of a genetically unrelated organ must be kept in the context of otherwise unrestricted host immune competence to any potential threat that jeopardizes the host. Nevertheless, transplant tolerance does not mean complete unresponsiveness of the immune system toward the graft; rather, it represents a lack of destructive immune response toward it in the presence of generalized immune competence.
In this issue of Current Opinion in Organ Transplantation a group of world-renowned experts in the field reviews the most recent and promising approaches to the induction of tolerance that have emerged from experimental animal studies, with the purpose of understanding whether and how close we are to clinical transplantation.
Fabricius and Zavazava discuss the potential benefit but also the hurdles and limitations of the possible application of embryonic stem cells (ESC) in the induction of transplantation tolerance. Recently significant progress has been made to direct in vitro and in vivo ESC to differentiate into specific tissues, including hematopoietic cells. Achievement of mixed chimerism by the use of donor ESC could facilitate the induction of tolerance in the transplant setting. Published evidence suggests that ESC are immune-privileged in allogeneic combinations. One of the protective mechanisms against host T cellmediated rejection could be the constitutional expression of FasL by ESC, but many other factors seem to contribute to this unique property that could be exploited for the induction of transplantation tolerance. Al-though the low immunogenicity of ESC may provide an advantage over hematopoietic stem cells, several hurdles, including our little knowledge of the robustness of ESC immune privilege and the underlying mechanisms, remain before clear concepts can be worked out for the use of ESC in clinical organ transplantation.
Goldman et al. analyze current knowledge on the unique effectiveness of hematopoietic stem cell (HSC) transplantation in inducing tolerance to vascularized organs and tissue. Transplantation of donor HSC allows in the recipient the coexistence of hematopoietic cell populations of both the host and the donor, the so-called mixed hematopoietic chimerism, a condition that may result in permanent acceptance of allografts in experimental animals while leaving the recipient immunocompetent toward other foreign antigens. Moreover, allogeneic bone marrow transplantation (which also includes HSC) to patients with hematologic malignancies has demonstrated successful tolerance induction in chimeric hosts who received a second-set kidney from the same donor. These grafts were well tolerated without any immunosuppression. Successful engraftment of allogeneic HSC requires recipients T cells to be destroyed by cytoreductive treatments such as irradiation, cytotoxic drugs, and anti-T cell antibodies, which, however, are still too toxic to be transferred to routine human solid organ transplant programs. Recent, experimental studies have provided key clues to minimizing the intensity of the conditioning treatment required for the successful induction of mixed chimerism and transplantation tolerance after the administration of allogeneic hematopoietic cells. Increasing the dose of the transplanted cells, blockade of costimulatory pathways of T cell activation with specific antibodies, and rapamycin were all found to promote engraftment of allogeneic hematopoietic cells and subsequent acceptance of tissue or organ transplant tolerance. New advances in HSC biology and the mechanisms throughout these cells may direct the host toward immune tolerance are now required to accomplish the remaining major steps in the direction of their safety and effective use in the clinical organ transplant setting.
Along this line, the Noris group focuses on the attempts to dissect possible mechanisms of tolerance induction by donor hematopoietic cell infusion. In the past few years we have learned from animal models of mixed chimeras that the induction and maintenance of tolerance to MHC-mismatched graft is a multistep, multifaceted process that encompasses clonal deletion of donor-reactive T cells in the thymus and peripheral lymphoid tissues, as well as immunoregulatory processes. Deletion and regulation are highly complementary, and both may well be necessary for long-term transplant tolerance to be achieved. The implementation of our knowledge into the molecular pathways underlying activation of these deletional and regulatory processes and how they are maintained with time are instrumental to design feasible and safe clinical tolerogenic protocols.
The phenomenon of active immunosuppression by regulatory T cells is under scrutiny by Cravedi and Aiello. Several subsets of regulatory T cells with distinct phenotypes and mechanisms of action have now been identified. They constitute a network of heterogeneous CD4 + or CD8 + T cell subsets and other minor T cell populations such as nonpolymorphic CD1d-responsive natural killer T cells. Regulatory T cells not only contribute to maintain self-tolerance and prevent autoimmune disease but also can be induced by tolerance protocols. As shown in several animal models, they play a role in preventing allograft rejection. Also, in stable transplant patients both CD4 + and CD8 + regulatory T cells have been documented to modulate the immune response toward donor antigens. Although much cellular and molecular characterization has been performed on these cells, there are still many unanswered questions. At the forefront are the following: How do regulatory T cells deliver the suppressive signal? What is the interaction between different regulatory T cell populations or regulatory dendritic cells?
The Thomson group surveys recent insights and advances in basic and applied dendritic cell biology that provide the foundation for manipulation of the in vivo function of these important antigen-presenting cells and for their ex vivo manipulation to promote transplantation tolerance. Traditionally, dendritic cells are believed to possess properties aimed at sensitizing T lymphocytes specific for foreign antigens. Now, dendritic cells have also become the focus of intense interest as regulators of immune response, and it is clear that dendritic cell maturation and/or function can be manipulated to promote their tolerogenicity with potential for therapeutic application in organ transplantation.
The precise impact of the conventional immunosuppressive drugs on tolerizing strategies by donor hematopoietic cell infusion is an additional important issue to be solved. This challenge is here addressed by Wekerle et al. Indeed, the initial suggestions that certain drugs impair the generation of tolerance in some models have not proved to be founded in other models.
Together, these findings indicate that although we are currently only at a very early stage, there is no doubt that in the near future some of these approaches will have a major impact on transplant medicine, opening a new perspective on indefinite graft survival without the complications of long-term immunosuppressive drugs, and contributing to make donor-specific tolerance in human transplantation a reality.
